More patients with prostate cancer being treated appropriately based on risk
the ONA take:
According to a study published in JAMA earlier this month, researchers at University of California, San Francisco, have found that patients with prostate cancer are now more likely to receive medical care matched to risk level.
Previous research has shown that patients with low-risk prostate cancer have been overtreated for decades and inadequately managed when the disease becomes more aggressive.
Now, researchers have determined that 40% of men with low-risk prostate cancer diagnosed between 2010 and 2013 opted for active surveillance compared with only 10% of patients with low-risk disease diagnosed between 1990 and 2009. Researchers also found that rates of radiotherapy for patients with low-risk disease have declined since 1995.
"We expected to see a rise in surveillance rates, but were surprised by the steepness of the trajectory. It shows a major shift toward appropriate, risk-adapted management of the disease," said corresponding author Matthew Cooperberg, MD, MPH, associate professor in the departments of Urology and Epidemiology & Biostatistics at UCSF, and Helen Diller Family chair in Urology at the UCSF Helen Diller Family Comprehensive Cancer Center.
Patients with prostate cancer are now more likely to receive medical care matched to risk level.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|